EUVIMEDEUVIMED entdecken
Crossref

Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents

Takahiro Ishii iD, Takuya Kobayakawa, Kouki Matsuda, Kiyomi Nigorikawa, Peter Bolah, Airi Noborio, Kohei Tsuji iD, Nami Ohashi, Kazuhisa Yoshimura, Wataru Nomura iD, Hiroaki Mitsuya, Kenji Maeda und 1 weitere

ACS Infectious Diseases · 2024

DOI: 10.1021/acsinfecdis.4c00194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Takahiro Ishii und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda-ku, Tokyo 101-00…. Hauptthemen laut MEDLINE: HIV-1, Virus Latency, Lactones, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toward human immunodeficiency virus type-1 (HIV-1) cure, cells latently infected with HIV-1 must be eliminated from people living with HIV-1. We previously developed a protein kinase C (PKC) activator, diacylglycerol (DAG)-lactone derivative 3, with high HIV-1 latency-reversing activity, based on YSE028 (2) as a lead compound and found that the activity was correlated with binding affinity for PKC and stability against esterase-mediated hydrolysis. Here, we synthesized new DAG-lactone derivatives not only containing a tertiary ester group or an isoxazole surrogate but also several symmetric alkylidene moieties to improve HIV-1 latency reversing activity. Compound 9a, with a dimethyl group at the α-position of the ester group, exerted twice higher HIV-1 latency reversing activity than compound 3, and compound 26, with the isoxazole moiety, was significantly active. In addition, DAG-lactone derivatives with moderate hydrophobicity and potent biostability showed high biological activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Virus LatencyLactonesAnti-HIV AgentsHumansDiglyceridesHIV InfectionsProtein Kinase C

Stichwörter der Autor:innen

DAG-lactoneHIV curePKC activatorbioisostereshock and kill

Substanzen

LactonesAnti-HIV AgentsDiglyceridesProtein Kinase C

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), Chiyoda-ku, Tokyo 101-0062, Japan.
  • Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Kagoshima 890-8544, Japan.
  • Department of Genome and Biomolecular Engineering for Drug Discovery, School of Pharmaceutical Sciences and Graduate School of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima 734-8553, Japan.
  • Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
  • Institute of Public Health, Bureau of Social Welfare and Public Health, Tokyo Metropolitan Government, Shinjuku-ku, Tokyo 169-0073, Japan.
  • Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Shinjuku-ku, Tokyo 162-8655, Japan.

ORCID-Profile: Takahiro Ishii, Kohei Tsuji, Wataru Nomura, Hirokazu Tamamura

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Ishii, T., Kobayakawa, T., Matsuda, K., Nigorikawa, K., Bolah, P., Noborio, A., Tsuji, K., Ohashi, N., Yoshimura, K., Nomura, W., Mitsuya, H., Maeda, K., & Tamamura, H. (2024). Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00194

Vancouver

Ishii T, Kobayakawa T, Matsuda K, Nigorikawa K, Bolah P, Noborio A, et al. Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00194

BibTeX
@article{Ishii2024,
  author = {Ishii, Takahiro and Kobayakawa, Takuya and Matsuda, Kouki and Nigorikawa, Kiyomi and Bolah, Peter and Noborio, Airi and Tsuji, Kohei and Ohashi, Nami and Yoshimura, Kazuhisa and Nomura, Wataru and Mitsuya, Hiroaki and Maeda, Kenji and Tamamura, Hirokazu},
  title = {Discovery of Potent DAG-Lactone Derivatives as HIV Latency Reversing Agents},
  journal = {ACS Infectious Diseases},
  year = {2024},
  doi = {10.1021/acsinfecdis.4c00194}
}
Kostenlos starten →